In a long-term collaboration, Ksilink and myriamed jointly established and validated an induced pluripotent stem cell (iPSC)-derived model of dilated cardiomyopathy (DCM), which will now be exploited by the newly created joint venture ‘Myrtil Biotechnologies’.
DCM is a life-threatening disease in which the heart becomes enlarged and cannot pump blood effectively anymore. About 1 in 2,500 people are affected with an onset most often in middle age and a poor five-year survival rate of only 50%. Familial forms of DCM are caused by a number of disease-causing mutations, the most frequent being C-terminal truncations in the TTN gene, so called titin-truncating variants (TTNtvs). Despite tremendous efforts in research and development, there is currently no disease-modifying treatment option available in the clinics. In fact, traditional drug discovery based on biochemical assays and animal models that are not correctly reflecting the human physiology has reached its limits. With new technologies in human stem cell biology, cell differentiation techniques, tissue engineering, and high-content imaging coupled to artificial intelligence (AI)-driven image and data analyses, there is a huge opportunity to reinvent drug discovery that Ksilink and myriamed have taken.
Thus, with the ambition to revolutionize therapeutic options for DCM patients, myriamed and Ksilink have embarked in a precision medicine approach, implementing human iPSC-derived cardiomyocytes, engineered to express a TTNtv mutation in 2D and 3D cardiac models. Titin (TTN) is the largest human protein with a pivotal role in heart muscle function. Heterozygous TTNtv mutations are commonly found in DCM patients. Myrtil Biotechnologies combines myriameds expertise in cardiac disease modelling and Ksilinks ability to functionalize complex cellular models for drug discovery purposes, leveraging on state-of-the-art high-content imaging coupled to AI-assisted image and data analyses tools, with the ambition of identifying innovative drug candidates, and to develop them into disease modifying therapies.
“We are very proud of this productive partnership” says Alain Beretz, president of the Ksilink Association. “Patient-based disease modeling for drug discovery purposes, empowered by AI-driven image analysis, is a strategic bet of Ksilink since its creation in 2014. The young company will benefit from the strong network of excellence of our French-German Association with outstanding capacities to generate most valuable compounds for next generation medicine”.
“We are excited that our competences and capacities to emulate dilated cardiomyopathy in our innovative cardiomyocyte and engineered heart muscle models will now be explored to identify precision medicines to combat heart failure“ states Gunther Zimmermann, CEO of myriamed GmbH.
“With Myrtil Biotechnologies, the two partners Ksilink and myriamed want to accelerate the project and set the ground for the entry of investors.” says Antoine de Lacombe, Managing Director at Ksilink. “Investors and Pharma are awaiting new approaches to enable the development of drugs that eventually significantly improve patient’s life. Myrtil Biotechnologies enters the court with an excellent scientific and strategic background.
About myriamed GmbH: myriamed GmbH, with its headquarter in Göttingen, was founded in 2012 as spin-off from the University Medical Center Göttingen to exploit innovative cell and tissue models for drug discovery. myriamed integrates unique proprietary heart, skeletal, brain, and connective tissue cell (myrCell) and tissue (myrTissue) models in versatile disease modelling platforms (myrDisease) to enable phenotypic high-throughput and high-content screens (myrScreen) in powerful patient-in-the-dish models. At myriamed, we are convinced, that the next generation cures with predictable safety and efficacy profiles will be discovered and developed in human disease models. With its world-class expertise and offerings of disruptive cell and tissue technologies myriamed strives to be a premium partner for ambitious drug developers. www.myriamed.com
DCM is a life-threatening disease in which the heart becomes enlarged and cannot pump blood effectively anymore. About 1 in 2,500 people are affected with an onset most often in middle age and a poor five-year survival rate of only 50%. Familial forms of DCM are caused by a number of disease-causing mutations, the most frequent being C-terminal truncations in the TTN gene, so called titin-truncating variants (TTNtvs). Despite tremendous efforts in research and development, there is currently no disease-modifying treatment option available in the clinics. In fact, traditional drug discovery based on biochemical assays and animal models that are not correctly reflecting the human physiology has reached its limits. With new technologies in human stem cell biology, cell differentiation techniques, tissue engineering, and high-content imaging coupled to artificial intelligence (AI)-driven image and data analyses, there is a huge opportunity to reinvent drug discovery that Ksilink and myriamed have taken.
Thus, with the ambition to revolutionize therapeutic options for DCM patients, myriamed and Ksilink have embarked in a precision medicine approach, implementing human iPSC-derived cardiomyocytes, engineered to express a TTNtv mutation in 2D and 3D cardiac models. Titin (TTN) is the largest human protein with a pivotal role in heart muscle function. Heterozygous TTNtv mutations are commonly found in DCM patients. Myrtil Biotechnologies combines myriameds expertise in cardiac disease modelling and Ksilinks ability to functionalize complex cellular models for drug discovery purposes, leveraging on state-of-the-art high-content imaging coupled to AI-assisted image and data analyses tools, with the ambition of identifying innovative drug candidates, and to develop them into disease modifying therapies.
“We are very proud of this productive partnership” says Alain Beretz, president of the Ksilink Association. “Patient-based disease modeling for drug discovery purposes, empowered by AI-driven image analysis, is a strategic bet of Ksilink since its creation in 2014. The young company will benefit from the strong network of excellence of our French-German Association with outstanding capacities to generate most valuable compounds for next generation medicine”.
“We are excited that our competences and capacities to emulate dilated cardiomyopathy in our innovative cardiomyocyte and engineered heart muscle models will now be explored to identify precision medicines to combat heart failure“ states Gunther Zimmermann, CEO of myriamed GmbH.
“With Myrtil Biotechnologies, the two partners Ksilink and myriamed want to accelerate the project and set the ground for the entry of investors.” says Antoine de Lacombe, Managing Director at Ksilink. “Investors and Pharma are awaiting new approaches to enable the development of drugs that eventually significantly improve patient’s life. Myrtil Biotechnologies enters the court with an excellent scientific and strategic background.
About myriamed GmbH: myriamed GmbH, with its headquarter in Göttingen, was founded in 2012 as spin-off from the University Medical Center Göttingen to exploit innovative cell and tissue models for drug discovery. myriamed integrates unique proprietary heart, skeletal, brain, and connective tissue cell (myrCell) and tissue (myrTissue) models in versatile disease modelling platforms (myrDisease) to enable phenotypic high-throughput and high-content screens (myrScreen) in powerful patient-in-the-dish models. At myriamed, we are convinced, that the next generation cures with predictable safety and efficacy profiles will be discovered and developed in human disease models. With its world-class expertise and offerings of disruptive cell and tissue technologies myriamed strives to be a premium partner for ambitious drug developers. www.myriamed.com
